| Literature DB >> 29059250 |
Hiroaki Nagano1, Takeshi Kinjo2, Yuichiro Nei1, Shin Yamashiro1, Jiro Fujita2, Tomoo Kishaba1.
Abstract
Nontuberculous mycobacteria (NTM) lung disease is increasing globally. Although the etiological epidemiology of NTM is different across regions, Mycobacterium avium complex (MAC) is the leading cause of NTM lung disease in most countries, including mainland Japan. Okinawa is located in the southernmost region of Japan and is the only prefecture categorized as a subtropical region in Japan, it is therefore likely the etiological epidemiology of NTM lung disease is different from mainland Japan. From 2009 to 2015, the medical records of patients, with respiratory specimens positive for NTMs, visiting or admitted to two Okinawan hospitals, were retrospectively analyzed. NTM lung disease cases were defined according to the American Thoracic Society criteria and patient epidemiology and clinical information were evaluated. Results indicate four hundred sixteen patients had bacterial cultures positive for NTM. The most common NTM was M. abscessus complex (MABC) (n = 127; 30.5%), followed by M. intracellulare (n = 85; 20.4%). NTM lung disease was diagnosed in 114 patients. Of these cases, MABC was most common (n = 41; 36.0%), followed by M. intracellulare (n = 31; 27.2%). Chronic obstructive pulmonary disease (COPD) and tracheostomy patients were more likely to develop MABC than MAC lung disease. Multivariate analysis showed a probable association between COPD and MABC lung disease. Chest computed tomography (CT) evaluation revealed bronchiectasis, nodules, and consolidation were less frequently observed in MABC patients compared with MAC patients. Our data suggests Okinawa may be one of the few places where MABC is the predominant pathogen causing NTM lung disease and our results add new insight to MABC lung disease, which is not yet well understood.Entities:
Mesh:
Year: 2017 PMID: 29059250 PMCID: PMC5653325 DOI: 10.1371/journal.pone.0186826
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1NTMs cultured from respiratory samples (N = 416).
NTMs isolated from respiratory specimens were retrospectively analyzed. Others category includes: Mycobacterium kansasii (1.0%), M. szulgai (0.7%), M. xenopi (0.7%), M. peregrium (0.5%), M. scrofulaceum (0.5%), M. simiae (0.2%), and M. terrae (0.2%).
Fig 2Epidemiology of NTM lung disease (N = 114).
NTM lung disease cases, defined according to the American Thoracic Society criteria, were extracted from NTM detected cases shown in Fig 1. Others category includes: Mycobacterium kansasii (0.9%), M. scrofulaceum (0.9%), M. szulgai (0.9%), M. terrae (0.9%), and M. xenopi (0.9%).
Patient background.
| MABC | MAC | ||
|---|---|---|---|
| [N = 41] | [N = 38] | ||
| Age (median) | 74 | 78.5 | 0.0567 |
| Sex (male) | 17 (41%) | 12 (32%) | 0.4840 |
| Smoking history | 17 (41%) | 14 (37%) | 1.0000 |
| Long-term care facility | 6 (15%) | 8 (21%) | 0.5600 |
| COPD | 10 (24%) | 2 (5%) | 0.0265 |
| Bronchial asthma | 7 (17%) | 3 (8%) | 0.3145 |
| Old healed tuberculosis | 7 (17%) | 6 (16%) | 1.0000 |
| Bronchiectasis | 6 (15%) | 4 (11%) | 0.7389 |
| Interstitial lung disease | 2 (5%) | 3 (8%) | 0.6675 |
| Thoracic surgery | 3 (7%) | 3 (8%) | 1.0000 |
| Tracheostomy | 6 (15%) | 0 | 0.0261 |
| Ventilator | 2 (5%) | 1 (3%) | 1.0000 |
| Tracheal cannulation | 6 (15%) | 1 (3%) | 0.1101 |
| Gastroesophageal disease | 4 (10%) | 3 (8%) | 1.0000 |
| Lung cancer | 1 (2%) | 0 | 1.0000 |
| Other solid cancer | 5 (12%) | 4 (11%) | 1.0000 |
| Hematological cancer | 1 (2%) | 0 | 1.0000 |
| Cardiovascular disease | 16 (39%) | 9 (24%) | 0.1564 |
| Chronic liver disease | 4 (10%) | 3 (8%) | 1.0000 |
| Chronic kidney disease | 7 (17%) | 6 (16%) | 1.0000 |
| Neuromuscular disease | 3 (7%) | 5 (13%) | 0.4711 |
| Cerebrovascular disease | 2 (5%) | 9 (24%) | 0.0221 |
| Autoimmune disease | 4 (10%) | 8 (21%) | 0.2148 |
| Diabetes mellitus | 6 (15%) | 4 (11%) | 0.7389 |
| HTLV-1 | 5 (12%) | 1 (3%) | 0.1409 |
| Corticosteroid | 9 (22%) | 8 (21%) | 1.0000 |
| Immunosuppressant | 5 (12%) | 2 (5%) | 0.4338 |
| Acid suppressant | 23 (56%) | 16 (42%) | 0.2629 |
*Only 76 and 19 patients had data included for smoking history and HTLV-1, respectively.
Patients admitted from long-term care facilities.
**Tracheal cannulation: includes tracheotomized patients and orally intubated patients.
Patients receiving daily corticosteroid at any dose.
Considered significant.
Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex, COPD; chronic obstructive pulmonary disease, HTLV-1; human T-lymphotropic virus 1
Multivariate analysis to determine clinical charecteristics for MABC.
| Odds ratio | 95% CI | ||
|---|---|---|---|
| COPD | 6.73 | 1.31–34.64 | 0.0225 |
| Tracheal cannulation | 6.45 | 0.69–60.44 | 0.1025 |
| Bronchiectasis | 1.56 | 0.36–6.71 | 0.5474 |
| Gastroesophageal disease | 1.23 | 0.22–6.96 | 0.8157 |
| Old healed tuberculosis | 0.91 | 0.24–3.44 | 0.8854 |
*Considered significant.
**Tracheal cannulation: includes tracheotomized patients and orally intubated patients.
Abbreviations: COPD; chronic obstructive pulmonary disease, CI; confidence interval
Symptoms.
| MABC | MAC | ||
|---|---|---|---|
| [N = 41] | [N = 38] | ||
| Fever (≧38°C) | 9 (22%) | 9 (24%) | 1.0000 |
| Cough | 16 (39%) | 18 (47%) | 0.5009 |
| Sputum | 31 (76%) | 27 (71%) | 0.7995 |
| Hemosputum | 4 (10%) | 5 (13%) | 0.7312 |
| Weight loss | 2 (5%) | 0 | 0.4943 |
*Weight loss was defined as decrease of more than 5% of body weight in 6 months.
Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex
Chest CT findings.
| MABC | MAC | ||
|---|---|---|---|
| [N = 40] | [N = 36] | ||
| Bronchiectasis | 21 (53%) | 29 (81%) | 0.0150 |
| Nodules | 14 (35%) | 25 (69%) | 0.0032 |
| Consolidation | 17 (43%) | 25 (69%) | 0.0224 |
| Cavity | 2 (5%) | 3 (8%) | 0.6631 |
| Ground-glass opacity | 9 (23%) | 7 (19%) | 0.7851 |
| Linear scarring | 30 (75%) | 26 (72%) | 0.8003 |
In total, 67 patients had more than one finding.
*Considered significant.
Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex